Display options
Cite
Mahabadi M, Norouzi M, Alavian SM, et al. Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients. Hepat Mon. 2013;13(1):e6712doi: 10.5812/hepatmon.6712.
Mahabadi, M., Norouzi, M., Alavian, S. M., Samimirad, K., Azad, T. M., Saberfar, E., Mahmoodi, M., Ramezani, F., Karimzadeh, H., Malekzadeh, R., Montazeri, G., Nejatizadeh, A., Ziaee, M., Abedi, F., Ataei, B., Yaran, M., Sayad, B., Hossein Somi, M., Sarizadeh, G., Sanei-Moghaddam, I., Mansour-Ghanaei, F., Rafatpanah, H., Pourhosseingholi, M. A., Keyvani, H., Kalantari, E., Saberifiroozi, M., Ali Judaki, M., Ghamari, S., Daram, M., Fazeli, Z., Goodarzi, Z., Khedive, A., Moradi, A., & Jazayeri, S. M. (2013). Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients. Hepatitis monthly, 13(1), e6712. https://doi.org/10.5812/hepatmon.6712
Mahabadi, Mostafa, et al. "Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients." Hepatitis monthly vol. 13,1 (2013): e6712. doi: https://doi.org/10.5812/hepatmon.6712
Mahabadi M, Norouzi M, Alavian SM, Samimirad K, Azad TM, Saberfar E, Mahmoodi M, Ramezani F, Karimzadeh H, Malekzadeh R, Montazeri G, Nejatizadeh A, Ziaee M, Abedi F, Ataei B, Yaran M, Sayad B, Hossein Somi M, Sarizadeh G, Sanei-Moghaddam I, Mansour-Ghanaei F, Rafatpanah H, Pourhosseingholi MA, Keyvani H, Kalantari E, Saberifiroozi M, Ali Judaki M, Ghamari S, Daram M, Fazeli Z, Goodarzi Z, Khedive A, Moradi A, Jazayeri SM. Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients. Hepat Mon. 2013 Jan 20;13(1):e6712. doi: 10.5812/hepatmon.6712. Print 2013 Jan. PMID: 23596461; PMCID: PMC3626233.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2013 Jan 20;13(1):e6712. doi: 10.5812/hepatmon.6712. Print 2013 Jan.

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.

Hepatitis monthly

Mostafa Mahabadi, Mehdi Norouzi, Seyed Moayyed Alavian, Katayoon Samimirad, Talat Mokhtari Azad, Esmaeil Saberfar, Mahmood Mahmoodi, Fatemeh Ramezani, Hadi Karimzadeh, Reza Malekzadeh, Ghodrat Montazeri, Azim Nejatizadeh, Masood Ziaee, Farshid Abedi, Behrooz Ataei, Majid Yaran, Babak Sayad, Mohammad Hossein Somi, Gholamreza Sarizadeh, Ismaeil Sanei-Moghaddam, Fariborz Mansour-Ghanaei, Houshang Rafatpanah, Mohammad Amin Pourhosseingholi, Hossain Keyvani, Ebrahim Kalantari, Mehdi Saberifiroozi, Mohammad Ali Judaki, Shiva Ghamari, Maryam Daram, Zeinab Fazeli, Zahra Goodarzi, Abolfazl Khedive, Abdolvahab Moradi, Seyed Mohamad Jazayeri

Affiliations

  1. Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran.

PMID: 23596461 PMCID: PMC3626233 DOI: 10.5812/hepatmon.6712

Abstract

BACKGROUND: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.

OBJECTIVES: The aim of this study was to characterize the hepatitis B virus reverse transcriptase (RT) protein variations among Iranian chronic HBV carriers who did not receive any antiviral treatments.

MATERIALS AND METHODS: Hepatitis B virus partial RT genes from 325 chronic in active carrier patients were amplified and directly sequenced. Nucleotide/amino acid substitutions were identified compared to the sequences obtained from the database.

RESULTS: All strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n = 13), (SVQ) 17.23% (n = 56), (M204I/V + L180M) 2.45% (n = 8) and (M204I) 2.76% (n = 9) of patients, respectively.

CONCLUSIONS: RT mutants do occur naturally and could be found in HBV carriers who have never received antiviral therapy. However, mutations related to drug resistance in Iranian treatment-naïve chronic HBV patients were found to be higher than other studies published formerly. Chronic HBV patients should be monitored closely prior the commencement of therapy to achieve the best regimen option.

Keywords: Drug-Resistance; Hepatitis B Virus; Iran; Therapy

References

  1. J Hepatol. 2006 Feb;44(2):422-31 - PubMed
  2. J Gastrointestin Liver Dis. 2007 Dec;16(4):403-6 - PubMed
  3. J Gastroenterol Hepatol. 2006 Dec;21(12):1783-8 - PubMed
  4. J Hepatol. 2006 Feb;44(2):283-90 - PubMed
  5. Hepatology. 2001 Jun;33(6):1527-32 - PubMed
  6. Hepat Mon. 2010 Winter;10(1):42-7 - PubMed
  7. J Viral Hepat. 2009 Feb;16(2):113-20 - PubMed
  8. Clin Infect Dis. 2003 Mar 15;36(6):687-96 - PubMed
  9. J Virol. 2003 Nov;77(21):11833-41 - PubMed
  10. J Mol Biol. 2003 Oct 24;333(3):553-63 - PubMed
  11. Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4448-52 - PubMed
  12. J Gastroenterol Hepatol. 2009 Aug;24(8):1417-23 - PubMed
  13. Gastroenterology. 2007 Apr;132(4):1574-85 - PubMed
  14. Hepat Mon. 2010 Fall;10(4):289-93 - PubMed
  15. Vet Res. 2010 Nov-Dec;41(6):38 - PubMed
  16. Virus Res. 2005 Feb;107(2):129-39 - PubMed
  17. J Clin Invest. 2001 Feb;107(4):449-55 - PubMed
  18. Int J Infect Dis. 2008 May;12(3):252-5 - PubMed
  19. Gene. 2006 Dec 15;384:129-38 - PubMed
  20. Hepatology. 2000 Jun;31(6):1318-26 - PubMed
  21. J Hepatol. 2006 Mar;44(3):593-606 - PubMed
  22. AIDS Rev. 2008 Apr-Jun;10(2):93-109 - PubMed
  23. Int J Infect Dis. 2008 Jan;12(1):83-7 - PubMed
  24. Hepatology. 2007 Jul;46(1):254-65 - PubMed
  25. Semin Liver Dis. 2006 May;26(2):162-70 - PubMed
  26. Hepatol Int. 2008 Jun;2(2):147-51 - PubMed
  27. Antiviral Res. 2009 Feb;81(2):147-55 - PubMed
  28. J Med Virol. 1999 Nov;59(3):270-6 - PubMed
  29. N Engl J Med. 2005 Jun 30;352(26):2673-81 - PubMed
  30. Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1150-8 - PubMed
  31. Antiviral Res. 2010 Jul;87(1):74-7 - PubMed
  32. Pathol Biol (Paris). 2010 Aug;58(4):245-53 - PubMed
  33. J Infect Dis. 2009 May 1;199(9):1275-85 - PubMed
  34. Int J Infect Dis. 2011 Feb;15(2):e78-121 - PubMed
  35. J Viral Hepat. 2006 Jul;13(7):427-34 - PubMed
  36. J Virol. 2000 Apr;74(8):3543-7 - PubMed
  37. J Mol Biol. 2004 May 28;339(2):405-12 - PubMed
  38. Antiviral Res. 2010 Mar;85(3):512-9 - PubMed
  39. J Mol Biol. 2003 Aug 1;331(1):213-29 - PubMed
  40. Clin Liver Dis. 2010 Aug;14(3):439-59 - PubMed
  41. J Virol. 1998 Mar;72(3):1725-30 - PubMed
  42. J Hepatol. 2005 Dec;43(6):920-3 - PubMed
  43. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):279-82 - PubMed
  44. Eur J Gastroenterol Hepatol. 2010 Jun;22(6):736-40 - PubMed
  45. J Infect Dis. 2007 Nov 15;196(10):1483-6 - PubMed

Publication Types